



EXPRESS MAIL NO.: EV475142357US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: George W. Muller *et al.*

Confirmation No.: 3369

Serial No.: 10/715,184

Group Art Unit: 1614

Filed: November 17, 2003

Examiner: Michel Graffeo

For: METHODS OF USING AND COMPOSITIONS  
COMPRISING (-)-3-(3,4-DIMETHOXY-  
PHENYL)-3-(1-OXO-1,3-DIHYDRO-  
ISOINDOL-2-YL)-PROPIONAMIDE

Attorney Docket No.: 9516-057-999  
(CAM No.: 501872-999056)

**SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **C11-C18** listed on the attached Substitute for Form PTO 1449 entitled "Information Disclosure Statement By Applicant." Copies of references **C11-C18** are provided herewith. This Information Disclosure Statement supplements the Information Disclosure Statements filed on September 22, 2004 and December 30, 2005.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action

05/16/2006 MBIZUNES 00000066 503013 10715184

01 FC:1806 180.00 DA


NYJD-1614200v1

NYJD: 1614200.1

under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the \$180.00 fee set forth in 37 C.F.R. §1.17(p) and any other fees that may be due in connection with this filing to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: May 10, 2006

	(Reg. No.)
Yehsil Moon	52,042
For: Anthony M. Insogna	35,203
<b>JONES DAY</b>	
222 East 41 <sup>st</sup> Street	
New York, New York 10017	
(212) 326-3939	

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use several sheets if necessary)ATTY DOCKET NO.  
9516-057-999  
(CAM No. 501872-999056)APPLICATION NO.  
10/715,184

## APPLICANT:

Muller et al.

FILING DATE:  
November 17, 2003

ART UNIT: 1614      CONF. NO.: 3369

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01				
	A02				
	A03				
	A04				
	A05				

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01						
	B02						
	B03						
	B04						

EXAMINER'S INITIALS*	NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)	
	C11	DREDGE et al., 2003, "Angiogenesis inhibitors in cancer therapy," <i>Curr. Opin. Investig. Drugs</i> 4(6):667-674
	C12	DREDGE et al., 2002, "Immunological effects of thalidomide and its chemical and functional analogs," <i>Crit. Rev. Immunol.</i> 22(5-6):425-437
	C13	DREDGE et al., 2002, "Recent developments in antiangiogenic therapy," <i>Expert Opin. Biol. Ther.</i> 2(8):953-966
	C14	GEE et al., 2003, "Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition," <i>Cancer Res.</i> 63(23):8073-8078
	C15	MARRIOTT et al., 2001, "Immunotherapeutic and antitumour potential of thalidomide analogues," <i>Expert Opin. Biol. Ther.</i> 1(4):1-8
	C16	MARRIOTT et al., 2002, "Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells," <i>Clin. Exp. Immunol.</i> 130(1):75-84
	C17	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," <i>Br. J. Haematol.</i> 124(3):366-375
	C18	MULLER et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production," <i>Bioorg. Med. Chem. Lett.</i> 9(11):1625-1630

EXAMINER  
NYJD-1614188v1

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.